Construction of a novel vector expressing Survivin-shRNA and fusion suicide gene yCDglyTK and its application in inhibiting proliferation and migration of colon cancer cells

Despite progress achieved in cancer chemotherapy in recent decades, adverse effects remain a limiting factor for a number of patients with colorectal cancer, suggesting the requirement for novel therapeutic strategies. Gene therapy appears to be a promising strategy for treating cancer. The present...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2017-11, Vol.14 (5), p.4721-4728
Main Authors: Ye, Ling, Yang, Yuan, Ma, Xin-Yu, Li, Dan, Xu, Mei-Li, Tan, Pan, Long, Li-Min, Wang, Hai-Qin, Liu, Ting, Guo, Yong-Hong
Format: Article
Language:English
Subjects:
Apoptosis
Cancer therapies
Care and treatment
Cell cycle
Chemotherapy
Colon cancer
Colorectal cancer
combination gene therapy
Cytotoxicity
Deoxyribonucleic acid
DNA
Enzymes
Fibroblasts
Gene expression
Gene therapy
Genetic aspects
Kinases
Metabolites
Metastasis
Plasmids
Proteins
RNA
RNAi
suicide gene
Survivin
Telomerase
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite progress achieved in cancer chemotherapy in recent decades, adverse effects remain a limiting factor for a number of patients with colorectal cancer, suggesting the requirement for novel therapeutic strategies. Gene therapy appears to be a promising strategy for treating cancer. The present study aimed to investigate the anti-tumor effect of a combined gene therapy, using Survivin downregulation by RNAi and a fusion suicide gene yCDglyTK therapy system. A triple-gene vector expressing Survivin-targeted small hairpin RNA (Survivin-shRNA) and fusion suicide gene yCDglyTK was constructed, and administered to HCT116 cells. Survivin expression decreased significantly and yCDglyTK fusion gene expression was confirmed by both reverse transcription-quantitative polymerase chain reaction and western blot analysis. Introduction of Survivin-shRNA into yCDglyTK/prodrug system eradicated colon cancer cells and induced apoptosis more effectively. Furthermore, this therapeutic system is able to inhibit the migration of HCT116 cells. These results indicate that the recombinant plasmid may serve as a novel gene therapy approach to treat colorectal carcinoma.
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2017.5154